RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/SHA-384/F6FDAA4E87DD2288ECA44B762CEEBC2DD896FB2FDAB2EB2C86A641A82B2E990C0164567AD3486E8A67ED9C8DCEBB90A2http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/F6FDAA4E87DD2288ECA44B762CEEBC2DD896FB2FDAB2EB2C86A641A82B2E990C0164567AD3486E8A67ED9C8DCEBB90A2http://www.w3.org/2000/01/rdf-schema#comment"Ongoing research may yield other treatments especially for children who have not responded to Spinraza. A gene therapy delivered by adeno-associated virus type 9 (AAV9) is designed to replace or correct SMN1 . Cure SMA is supporting research in this area as well as studies of small molecules that correct SMN2 splicing or spur it to produce more protein."xsd:string
http://purl.uniprot.org/uniprot/#_294BC3E2E81401BAC82D7EE2807D66CB9CF4F5E063AADF918709445545844690E9E229F130B6F98883BF8D900FA23A7Dhttp://www.w3.org/1999/02/22-rdf-syntax-ns#subjecthttp://purl.uniprot.org/SHA-384/F6FDAA4E87DD2288ECA44B762CEEBC2DD896FB2FDAB2EB2C86A641A82B2E990C0164567AD3486E8A67ED9C8DCEBB90A2
http://purl.uniprot.org/uniprot/Q16637http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/F6FDAA4E87DD2288ECA44B762CEEBC2DD896FB2FDAB2EB2C86A641A82B2E990C0164567AD3486E8A67ED9C8DCEBB90A2
http://purl.uniprot.org/uniprot/#_Q16637-mappedCitation-28328128http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/F6FDAA4E87DD2288ECA44B762CEEBC2DD896FB2FDAB2EB2C86A641A82B2E990C0164567AD3486E8A67ED9C8DCEBB90A2